ArticleThe American journal of pathology2026
Machine Learning Predicts Adequacy of Rapid On-site Evaluation in Fine Needle Aspirations in Lung Cancer Cytology.
Article in The American journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung cancer is projected to become the leading cause of cancer-related mortality in both smoking and nonsmoking populations. Rapid on-site evaluation (ROSE) of fine needle aspiration specimens is essential for timely diagnosis and procedural decision-making during lung cancer assessment. A machine learning pipeline was developed for cell-based adequacy assessment and lesion detection that integrates automated cell detection, convolutional neural network-based cell classification, and slide-level aggregation using a random forest model. On held-out test data, binary classifiers for lymphocytes and tumor cells achieved accuracies of 91.5% and 92.7% with recalls of 92.6% and 93.1%, respectively. The end-to-end ROSE system demonstrated class accuracies of 82% to 85%, comparable with human cytologist performance, and a lesion-focused classifier reached a recall of 92.0%. These findings indicate that machine learning-based cell analysis can support ROSE by expediting adequacy assessment and improving diagnostic yield during transbronchial needle aspiration procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.